About cargo therapeutics inc. - CRGX
Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Carlos, CA.
CRGX At a Glance
Cargo Therapeutics, Inc.
835 Industrial Road
San Carlos, California 94070
| Phone | 1-650-449-8950 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -98,147,000.00 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
CRGX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.353 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.20 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.049 |
CRGX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CRGX Liquidity
| Current Ratio | 19.35 |
| Quick Ratio | 19.35 |
| Cash Ratio | 19.173 |
CRGX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -42.371 |
| Return on Equity | -53.031 |
| Return on Total Capital | -22.618 |
| Return on Invested Capital | -49.382 |
CRGX Capital Structure
| Total Debt to Total Equity | 7.04 |
| Total Debt to Total Capital | 6.577 |
| Total Debt to Total Assets | 6.30 |
| Long-Term Debt to Equity | 6.479 |
| Long-Term Debt to Total Capital | 6.052 |